StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)

Close on Nov 17, 2026Market cap $226.53MP/E –Yield –

Arcturus Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Arcturus Therapeutics's price to sales ratio was 9.0× on Nov 11, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 1.7× to 110.8×, with a median of 3.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20269.0×+7.3
2025Dec 31, 20251.7×−1.2
2024Dec 31, 20242.9×+0.0
2023Dec 29, 20232.8×−5.9
2022Dec 30, 20228.7×−102.1
2021Dec 31, 2021110.8×+7.4
2020Dec 31, 2020103.4×+96.9
2019Dec 31, 20196.5×–

More Arcturus Therapeutics figures

See a number that looks wrong?